Results 121 to 130 of about 106,775 (245)

Association Between Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Atrial Fibrillation Adverse Events: A Systematic Review and Meta-Analysis of Randomized Trials [PDF]

Henry O Aiwuyo, Irikefe P. Obiebi, Osagioduwa Mike Atoe-Imagbe, Uyilawa Okhuaihesuyi, John O Osarenkhoe, Anthony G Kweki, Christopher O Iruolagbe, Isa O Oboirien, Oluwasegun Matthew Akinti, Emmanuel Chinonso Okakpu, Ogie Derick Aghimien, Ovie Okorare, Jamal C Perry, Donald Tchapmi   +13 more
openalex   +1 more source

DNA methylation of the glucagon-like peptide 1 receptor (GLP1R) in human pancreatic islets [PDF]

, 2013
Elin Hall, Tasnim Dayeh, Clare L. Kirkpatrick, Claes B. Wollheim, Marloes Dekker Nitert, Charlotte Ling   +5 more
openalex   +1 more source

Dermatological Manifestations of Glucagon‐Like Peptide‐1 Receptor Agonists [PDF]

Nour Ghostine, M. Halabi‐Tawil
openalex   +1 more source

Additional file 5: of Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies

, 2016
Ling Li, S Li, Jiali Liu, Ke Deng, Jason W. Busse, Per Olav Vandvik, Evelyn M. Wong, Zahra Sohani, Malgorzata Bala, Lorena P Rios, Germán Málaga, Shanil Ebrahim, Jiantong Shen, Longhao Zhang, Pujing Zhao, Qunfei Chen, Yingqiang Wang, Gordon Guyatt, Xin Sun   +18 more
openalex   +1 more source

Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy for the Treatment of Type 2 Diabetes: Are Two Agents Better Than One? [PDF]

, 2018
Vanita R. Aroda, Joseph R. Arulandu, Anthony J. Cannon   +2 more
openalex   +1 more source

Oral Glucagon-Like Peptide-1 Receptor Agonists for Preventing Cardiorenal Complications. [PDF]

Curr Cardiol Rep
Odeleye V, Singh N, Gautam S, Shannon E, Bibb WM, McClure M, Paul TK.   +6 more
europepmc   +1 more source

Acute Contractile Effects of Glucagon-like-Peptide-1 Receptor Agonists in the Human Heart. [PDF]

Pharmaceutics
Neumann J, Kirchhefer U, Hofmann B, Gergs U.   +3 more
europepmc   +1 more source

Cardiovascular and renal outcomes of dual combination therapies with glucagon-like peptide-1 receptor agonists and sodium-glucose transport protein 2 inhibitors: a systematic review and meta-analysis [PDF]

Arveen Shokravi, Jayant Seth, G.B.John Mancini   +2 more
openalex   +1 more source

Accumulation and attenuation of cardiovascular benefit with glucagon-like peptide 1 receptor agonists. [PDF]

BMJ Med
Batty JA, Del Toro T, Hall M.
europepmc   +1 more source

Survodutide - Novel Anti Obesity Drug

JK Science
Survodutide (BI 456906) is a novel, dual agonist of glucagon and glucagon-like peptide-1 (GLP-1) receptors developed as a once-weekly subcutaneous injection for the management of obesity.
Irtiqa Ayani Rathore, Sana Malik, Amarjeet Singh, Vishal R Tandon, Annil Mahajan   +4 more
doaj